ICYMI:
@notablelabs
poster, “Retrospective prediction of clinical response to standard-of-care therapies in acute myeloid leukemia by an ex vivo drug sensitivity assay using cryopreserved primary samples,” presented at the American Association for Cancer Research (
@AACR
) 2024 in
Check out
@notablelabs
poster, “Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for venetoclax-HMA relapsed/refractory acute myeloid leukemia patients,” presented last week at the
@AACR
2024 Annual Meeting in San Diego, CA
@notablelabs
will present the following two posters at the American Association for Cancer Research
(
@AACR
) Annual Meeting, April 5-10, 2024, in San Diego, CA:
1. Guided by a predictive ex vivo test: Bringing the PLK1 inhibitor volasertib back into the clinic for
Learn how
@notablelabs
is pioneering the integration of artificial intelligence (AI) into predictive precision medicine in this informative
@CALifeSciences
article, written by Chris Leonardi, Head of Clinical Alliances and Partnerships. Chris explores how predictive precision
@notablelabs
Predictive Precision Medicine Platform (PPMP) uses AI and machine learning to provide a predictive score for a patient's likelihood to respond to a particular cancer treatment. NOTABLE’s PPMP is designed to identify and select clinically responsive patients prior to
@notablelabs
announced the advancement of its volasertib Phase 2 program utilizing PPMP to enrich the study population for clinical responders. Notable is developing its lead drug asset volasertib with its proprietary PPMP for patients with relapsed/refractory acute myelogenous
The
@notablelabs
Predictive Precision Medicines Platform (“PPMP”) has been validated across four clinical studies conducted at global academic cancer research centers. Through our proprietary PPMP technology, Notable bio-simulates a cancer treatment and aims to predict whether a
Exemplifying the company's strong commitment to research and development of precision treatments for MDS,
@notablelabs
has donated $60,000 to the
@MDSFoundation
. The donation was formally announced during the MDS Foundation 2023 Satellite Symposium at the 65th
@ASH_hematology
ICYMI:
@notablelabs
was featured on the front page of the December 10/11, Hematology Daily News distributed at
@ASH_hematology
(
#ASH23
) conference in San Diego. The article, “The Promise of Predictive Medicine is Coming True,” explains how Notable Labs is advancing predictive
See
@notablelabs
Booth
#2454
@ASH_hematology
Dec. 9-12 & sched. meeting. Learn about PPMP & volasertib, potent PLK1 inhibitor proven to induce cell cycle arrest & apoptosis in various cancer cells. by Dec. 11 for exclusive event invite!
#ASH23
#AML
#MDS
Matching the RIGHT drug to the RIGHT patient is what we're all about. In an interview with our CEO, Thomas Bock highlights his own personal experience with cancer and how here at Notable we are using our platform to match oncology "diamonds in the rough" with the right patients.
.
@Notablelabs
CEO, Dr. Thomas Bock discusses how his personal experiences watching loved ones take cancer treatments motivated him to develop a new class of “predictive precision medicines.”
Congrats to the 2022 YC Top Companies!
This year, we also launched the YC Breakthrough Companies list to highlight the fast-growing companies that have received between $15M-$300M from YC:
Today is
#AMLWorldAwarenessDay
! Did you know acute myeloid
#leukemia
(AML) is a rare aggressive
#cancer
of the blood 🩸 & bone marrow, and makes up about 1% of cancers?
Let’s unite around the world 🌍, increase AML awareness, and support patients with
#bloodcancer
!
#KnowAML
On today, AML World Awareness Day, we'd like to take a second and acknowledge the 60,000+ individuals living, fighting, and coping with their AML diagnosis. You are warriors. You are strong. You are Notable.
#AMLWorldAwarenessDay
#leukemia
#CANCER
#PrecisionMedicine
Notable welcomes Kevin Lynch, PhD, MBA to Notable's executive team as Chief Business Officer accelerating our
#inlicensing
strategy to fuel our Predictive Precision Medicine Platform & Pipeline
#lifescienceleaders
#culture
#techbio
I'm excited to announce today’s co-development agreement with
@CicloMedLLC
. We continue to add to our pipeline of innovative therapies for patients with cancer in a new era of high-fidelity predictive precision medicine.
#drugdevelopment